Other OTC - Delayed Quote USD

UCB SA (UCBJY)

66.57

-0.28

(-0.42%)

As of 11:57 AM EDT. Market Open.

UCB SA's Dividend Analysis

UCB SA (UCBJY) recently announced a dividend of $0.73 per share, payable on 2024-05-15, with the ex-dividend date set for 2024-04-26. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into UCB SA's dividend performance and assess its sustainability.

GuruFocus.com yesterday

UCBJY
-0.42%
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting

UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced the latest research from its expansive neurology portfolio and pipeline to be presented at the 76th American Academy of Neurology (AAN) Annual Meeting, April 13-18, 2024, in Denver, Colorado, USA.

PR Newswire 14 days ago

UCBJF
+4.03%
UCBJY
-0.42%
UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa

UCB, a global biopharmaceutical company, today announced the launch of Make HStory, an educational campaign that provides tools and resources for those living with hidradenitis suppurativa (HS) and their dermatologists.

PR Newswire 16 days ago

UCBJF
+4.03%
UCBJY
-0.42%
FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations

UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for BIMZELX® (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS). In addition, a second sBLA for the BIMZELX 2mL device presentations has also been accepted.

PR Newswire 22 days ago

UCBJF
+4.03%
UCBJY
-0.42%
UCB Convening Notice to the General Meeting of the Shareholders 2024

CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS The Board of Directors invites the shareholders for the ordinary and extraordinary general meeting of the shareholders (the “General Meeting” or the “GM”) which will be held on Thursday, 25 April 2024, at 11:00 am CEST, at the registered office of UCB SA/NV, Allée de la Recherche 60 - 1070 Brussels, for the purpose of considering and voting on the items shown on the agenda set out below. Applicable participation formalities are detailed at

GlobeNewswire last month

UCBJF
+4.03%
UCBJY
-0.42%
First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis

UCB, a global biopharmaceutical company, today announced that the first presentations of BIMZELX® (bimekizumab-bkzx) four-year efficacy and safety data in the treatment of adults with moderate-to-severe plaque psoriasis are being shared this week at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, March 8–12.

PR Newswire last month

UCBJF
+4.03%
UCBJY
-0.42%
BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count

UCB, a global biopharmaceutical company, today announced 48-week post-hoc analyses of pooled Phase 3 data from the BE HEARD I and BE HEARD II studies examining the impact of BIMZELX on skin pain and draining tunnels in adults with moderate-to-severe hidradenitis suppurativa (HS). These results are shared at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, March 8–12.

PR Newswire last month

UCBJF
+4.03%
UCBJY
-0.42%
UCB on Growth Path for a Decade Plus

UCB Full-Year Report 2023 – regulated information

PR Newswire last month

UCBJF
+4.03%
UCBJY
-0.42%
20 Most Valuable Belgian Companies in 2024

In this article, we will be looking at the 20 most valuable Belgian companies in 2024. If you wish to skip our detailed analysis, you can move directly to the 5 Most Valuable Belgian Companies in 2024. Economy of Belgium: An Analysis Belgium has a small and open economy which recorded a GDP worth $627.51 […]

Insider Monkey 2 months ago

^GSPC

UCBJY
-0.42%
KBCSY
ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive

UCB, a global biopharmaceutical company, announced today that ZILBRYSQ® (zilucoplan) is now available in the U.S. for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. ZILBRYSQ was approved by the U.S. Food and Drug Administration (FDA) on October 17, 2023.1

PR Newswire 3 months ago

UCBJF
+4.03%
UCBJY
-0.42%
UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting

UCB, a global biopharmaceutical company, today announced data being presented at the American Epilepsy Society (AES) Annual Meeting, taking place December 1–5 in Orlando, Florida, that focus on the real-world experiences of people living with rare epilepsy syndromes and their caregivers, in addition to several other presentations of clinical data evaluating the efficacy, safety and tolerability of FINTEPLA as a treatment for seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndro

PR Newswire 4 months ago

UCBJF
+4.03%
UCBJY
-0.42%
UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

UCB, a global biopharmaceutical company, today unveiled its extensive program of 29 studies, including 4 late breakers, accepted for presentation at the AES Annual Meeting 2023, taking place from 1-5 December in Orlando, Florida.

PR Newswire 4 months ago

UCBJF
+4.03%
UCBJY
-0.42%
UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

UCB, a global biopharmaceutical company, announced today that BIMZELX® (bimekizumab-bkzx) is commercially available for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. BIMZELX was approved by the U.S. Food and Drug Administration (FDA) on October 17, 2023.

PR Newswire 5 months ago

UCBJF
+4.03%
UCBJY
-0.42%
Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)

UCB, a global biopharmaceutical company, will present a post hoc analysis of the EXXELERATE trial examining the efficacy of CIMZIA® (certolizumab pegol) and adalimumab in patients with rheumatoid arthritis (RA) with high rheumatoid factor (RF) levels. The data are being presented at the American College of Rheumatology (ACR) Convergence 2023 in San Diego, November 10–15.1

PR Newswire 5 months ago

UCBJF
+4.03%
UCBJY
-0.42%
UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023

UCB, a global biopharmaceutical company, today announced new long-term data from the BIMZELX® (bimekizumab) Phase 2b study BE AGILE and its open-label extension (OLE). Patients with ankylosing spondylitis (AS) treated with BIMZELX, an IL-17A and IL-17F inhibitor, showed sustained improvements in signs and symptoms, disease activity, physical function, and health-related quality of life for up to five years, with a consistent safety profile through five years of treatment.1 These data are being p

PR Newswire 5 months ago

UCBJF
+4.03%
UCBJY
-0.42%
UCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that it will be presenting results from across its portfolio in generalized myasthenia gravis (gMG) at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) annual meeting and the Myasthenia Gravis Association of America Scientific Session taking place November 1-4, 2023.

PR Newswire 5 months ago

UCBJF
+4.03%
UCBJY
-0.42%
NAYZILAM® (midazolam) Results Published in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB, a global biopharmaceutical company, today announced that Epilepsy & Behavior published a post hoc analysis from the Phase 3 open-label extension study of NAYZILAM. This analysis showed the estimated median time to RTFBF, regardless of treatment with one or two doses, was 90 minutes. While most patients required a single 5-mg spray to treat the cluster, patients and caregivers had the option to administer a second 5-mg dose after only 10 minutes if needed. This publication characterized the

PR Newswire 5 months ago

UCBJF
+4.03%
UCBJY
-0.42%
BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Regulated Information – Inside Information – UCB, a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved BIMZELX® (bimekizumab-bkzx) for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.1 BIMZELX is the first and only approved psoriasis treatment designed to selectively inhibit two key cytokines driving inflammatory processes – interleukin 17A (IL-17A) and interleukin

PR Newswire 6 months ago

UCBJF
+4.03%
UCBJY
-0.42%
UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis

UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that ZILBRYSQ® (zilucoplan) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive.1

PR Newswire 6 months ago

UCBJF
+4.03%
UCBJY
-0.42%
UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB, a global biopharmaceutical company, today announced that it will present six abstracts in hidradenitis suppurativa (HS) at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA), October 13–15 in Phoenix, Arizona. Data and analyses in HS will be presented across two oral presentations and four posters.

PR Newswire 6 months ago

UCBJF
+4.03%
UCBJY
-0.42%

Performance Overview

Return	UCBJY	BEL 20
YTD	+52.67%	+4.51%
1-Year	+40.89%	+1.28%
3-Year	+43.59%	-3.34%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

UCB SA (UCBJY)

UCB SA's Dividend Analysis

UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting

UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa

FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations

UCB Convening Notice to the General Meeting of the Shareholders 2024

First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis

BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count

UCB on Growth Path for a Decade Plus

20 Most Valuable Belgian Companies in 2024

ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive

UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting

UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)

UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023

UCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

NAYZILAM® (midazolam) Results Published in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

Performance Overview